Innate Pharma cashes $15million milestone payment from Bristol-Myers for lirilumab-Opdivo testing
Bristol-Myers Squibb (BMS) has reached a payment milestone in connection with the licensing deal with Innate Pharma for lirilumab in combination with Opdivo. BMS has paied Innate $15 million.